Sign in or create an account to add this stock to your watchlist.
About Aeglea Bio Therapeutics (NASDAQ:AGLE)
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers. Its preclinical pipeline products comprise AEB3103, an engineered human enzyme that targets the degradation of the amino acid cysteine/cysteine; and AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine, as well as AEB4104, an engineered human enzyme that targets the reduction of elevated levels of the amino acid homocysteine. Aeglea BioTherapeutics, Inc. has a clinical collaboration agreement with Merck to evaluate the combination of pegzilarginase with Merck's anti-PD1 therapy, pembrolizumab, for the treatment of patients with small cell lung cancer. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AGLE
CUSIPN/A
Phone512-942-2935
Debt
Debt-to-Equity RatioN/A
Current Ratio8.48
Quick Ratio8.48
Price-To-Earnings
Trailing P/E Ratio-5.90
Forward P/E Ratio-6.36
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.20 million
Price / Sales44.64
Cash FlowN/A
Price / CashN/A
Book Value$2.01 per share
Price / Book5.28
Profitability
EPS (Most Recent Fiscal Year)($1.80)
Net Income$-27,230,000.00
Net Margins-507.82%
Return on Equity-54.83%
Return on Assets-49.87%
Miscellaneous
Employees43
Outstanding Shares21,860,000
Aeglea Bio Therapeutics (NASDAQ:AGLE) Frequently Asked Questions
What is Aeglea Bio Therapeutics' stock symbol?
Aeglea Bio Therapeutics trades on the NASDAQ under the ticker symbol "AGLE."
How were Aeglea Bio Therapeutics' earnings last quarter?
Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) released its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.49) EPS for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.05. The biotechnology company had revenue of $1.51 million for the quarter. Aeglea Bio Therapeutics had a negative return on equity of 54.83% and a negative net margin of 507.82%. View Aeglea Bio Therapeutics' Earnings History.
What price target have analysts set for AGLE?
3 Wall Street analysts have issued 12 month price targets for Aeglea Bio Therapeutics' stock. Their predictions range from $18.00 to $37.00. On average, they expect Aeglea Bio Therapeutics' stock price to reach $25.00 in the next twelve months. View Analyst Ratings for Aeglea Bio Therapeutics.
Who are some of Aeglea Bio Therapeutics' key competitors?
Some companies that are related to Aeglea Bio Therapeutics include Arrowhead Pharmaceuticals (ARWR), Assembly Biosciences (ASMB), UroGen Pharma (URGN), Deciphera Pharmaceuticals (DCPH), Rhythm Pharmaceuticals (RYTM), Collegium Pharmaceutical (COLL), Theratechnologies (THERF), Rocket Pharmaceuticals (RCKT), Geron (GERN), InflaRx (IFRX), AMAG Pharmaceuticals (AMAG), Adamas Pharmaceuticals (ADMS), Amphastar Pharmaceuticals (AMPH), Vectura Group (VEGPF) and Abeona Therapeutics (ABEO).
Who are Aeglea Bio Therapeutics' key executives?
Aeglea Bio Therapeutics' management team includes the folowing people:
- Dr. Anthony G. Quinn, Interim CEO & Director (Age 56)
- Prof. George Georgiou Ph.D., Co-Founder and Director (Age 59)
- Mr. Charles N. York II, M.B.A., Chief Financial Officer and VP (Age 41)
- Dr. Scott W. Rowlinson Ph.D., VP of Research (Age 50)
- Dr. Leslie Sloan Ph.D., Sr. VP of Operations
When did Aeglea Bio Therapeutics IPO?
(AGLE) raised $60 million in an initial public offering on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager.
Has Aeglea Bio Therapeutics been receiving favorable news coverage?
Media coverage about AGLE stock has been trending very positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aeglea Bio Therapeutics earned a media sentiment score of 0.50 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 41.79 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Aeglea Bio Therapeutics' major shareholders?
Aeglea Bio Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include NOVARTIS BIOVENTURES LTD (9.80%), Dimensional Fund Advisors LP (0.42%), Millennium Management LLC (0.34%), JPMorgan Chase & Co. (0.30%), Blair William & Co. IL (0.12%) and UBS Group AG (0.11%). Company insiders that own Aeglea Bio Therapeutics stock include Anthony G Quinn, Bioventures Ltd Novartis, Charles N York II and Orbimed Advisors Llc. View Institutional Ownership Trends for Aeglea Bio Therapeutics.
Which major investors are buying Aeglea Bio Therapeutics stock?
AGLE stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co., UBS Group AG, A.R.T. Advisors LLC, Blair William & Co. IL, Stanley Laman Group Ltd. and Spark Investment Management LLC. Company insiders that have bought Aeglea Bio Therapeutics stock in the last two years include Anthony G Quinn, Charles N York II and Orbimed Advisors Llc. View Insider Buying and Selling for Aeglea Bio Therapeutics.
How do I buy shares of Aeglea Bio Therapeutics?
Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aeglea Bio Therapeutics' stock price today?
One share of AGLE stock can currently be purchased for approximately $10.62.
How big of a company is Aeglea Bio Therapeutics?
Aeglea Bio Therapeutics has a market capitalization of $216.18 million and generates $5.20 million in revenue each year. The biotechnology company earns $-27,230,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Aeglea Bio Therapeutics employs 43 workers across the globe.
How can I contact Aeglea Bio Therapeutics?
Aeglea Bio Therapeutics' mailing address is 901 SOUTH MOPAC EXPRESSWAY BARTON OAKS PLAZA ONE SUITE 250, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-942-2935 or via email at [email protected]
MarketBeat Community Rating for Aeglea Bio Therapeutics (AGLE)
MarketBeat's community ratings are surveys of what our community members think about Aeglea Bio Therapeutics and other stocks. Vote "Outperform" if you believe AGLE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGLE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aeglea Bio Therapeutics (NASDAQ:AGLE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Aeglea Bio Therapeutics in the last 12 months. Their average twelve-month price target is $25.00, suggesting that the stock has a possible upside of 135.40%. The high price target for AGLE is $37.00 and the low price target for AGLE is $18.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | N/A | N/A |
| Consensus Rating Score: | 3.00 | 3.00 | N/A | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $25.00 | $25.00 | N/A | N/A |
| Price Target Upside: | 135.40% upside | 216.46% upside | N/A | N/A |
Aeglea Bio Therapeutics (NASDAQ:AGLE) Consensus Price Target History
Aeglea Bio Therapeutics (NASDAQ:AGLE) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Aeglea Bio Therapeutics (NASDAQ:AGLE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Aeglea Bio Therapeutics (NASDAQ AGLE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 27.00%
Institutional Ownership Percentage: 37.65%
Aeglea Bio Therapeutics (NASDAQ AGLE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/10/2018 | Bioventures Ltd Novartis | Major Shareholder | Sell | 73,955 | $10.12 | $748,424.60 | |  |
| 5/7/2018 | Bioventures Ltd Novartis | Major Shareholder | Sell | 15,548 | $10.11 | $157,190.28 | | |
| 12/8/2017 | Anthony G Quinn | CEO | Buy | 8,288 | $4.96 | $41,108.48 | 32,009 | |
| 12/6/2017 | Anthony G Quinn | CEO | Buy | 4,888 | $4.92 | $24,048.96 | 32,009 | |
| 12/5/2017 | Charles N York II | CFO | Buy | 25,959 | $4.48 | $116,296.32 | 10,828 | |
| 12/4/2017 | Anthony G Quinn | Director | Buy | 7,956 | $4.98 | $39,620.88 | 14,100 | |
| 12/1/2017 | Anthony G Quinn | Director | Buy | 4,100 | $4.53 | $18,573.00 | 14,100 | |
| 12/1/2017 | Charles N York II | CFO | Buy | 6,500 | $4.59 | $29,835.00 | 10,828 | |
| 2/21/2017 | Orbimed Advisors Llc | Major Shareholder | Buy | 109,300 | $5.16 | $563,988.00 | | |
| 4/12/2016 | Anthony Quinn | Director | Buy | 10,000 | $10.00 | $100,000.00 | 10,000 | |
| 4/12/2016 | Bioventures Ltd Novartis | Major Shareholder | Buy | 300,000 | $10.00 | $3,000,000.00 | | |
(Data available from 1/1/2013 forward)
Aeglea Bio Therapeutics (NASDAQ AGLE) News Headlines
| Source: |
|
Aeglea Bio Therapeutics (NASDAQ:AGLE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aeglea Bio Therapeutics (NASDAQ:AGLE) Income Statement, Balance Sheet and Cash Flow Statement
Aeglea Bio Therapeutics (NASDAQ AGLE) Stock Chart for Friday, May, 25, 2018
Loading chart…
